Active, Not Recruiting
Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.
NCT04006262
- Conditions
- Genomic Instability, Localized Oesogastric Adenocarcimona, MSI and or dMMR, +3 more
- Locations
-
- CHRU Jean Minjoz Besançon, France
- Hôpital Henri Mondor Créteil, France
- Institut Hospitalier Franco-Britannique Levallois-Perret, France
- CHRU Lille Lille, France